^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

LYT-210

i
Other names: LYT-210
Associations
Trials
Company:
PureTech
Drug class:
γδ TCR modulator, Gamma delta-1 T cell modulator
Associations
Trials
over3years
[VIRTUAL] Efficacy and characterization of a specific and potent monoclonal antibody, LYT-210, against immunosuppressive gd1 T cell in cancer (AACR 2021)
We have developed a novel, therapeutic immuno-oncology strategy specifically targeting imunosuppressive γδ1cells. Our data support that this therapeutic approach may have the potential to be transformative for the treatment of cancers where γδ1T cells drive a pro-tumorigenic, immunosuppressive environment.
Clinical
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
LYT-210